


METASTATIC LEIOMYOSARCOMA

Personalized TumorGraft™ case study: 55-year-old female diagnosed with abdominal metastatic leiomyosarcoma who had 3 prior regimens¹

First-line adjuvant therapy with Gemcitabine/Docetaxel; second-line therapy with Ifosfamide; third-line with Adriamycin

PERSONALIZED TUMORGRAFT™ RESPONSE TO DRUG TESTING

First round of drug testing (fourth line of treatment)



1. Triple drug therapy (Gemcitabine, Docetaxel and Bevacizumab) resulted in a 50% reduction in tumor mass (partial response)
 - Patient remained in partial response for 9 months
2. Additional drug testing revealed that maximal response in the patient’s Personalized TumorGraft™ was achieved with Capecitabine combined with Temozolomide (fifth line of treatment)
 - This treatment was never used in leiomyosarcoma before
 - The patient’s tumor regressed (partial response) for 6 more months

Case study conclusion

- This treatment was never used before
- Patient responded to two courses of Champions-guided treatment
- Patient lived 15 months on late-line therapy

¹Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, et al. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther June 2011.